RNA, U6 small nuclear 1099, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1099P profile across patient tissues and cancer cell-line models. RNU6-1099P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU6-1099P is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, RNU6-1099P RNA expression shows 14,061 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUSC, and THYM as cancer lineages where RNU6-1099P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1099P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1099P survival associations across molecular data types. RNU6-1099P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1099P RNA expression–survival associations across cancer types. High RNU6-1099P expression shows unfavorable associations in UVM, UCEC, MESO, ACC and LGG, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU6-1099P RNA expression.
This table summarizes RNU6-1099P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1099P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1099P shows higher tumor expression in LUSC, HNSC, KIRC, UCEC, STAD and BRCA. The LUSC box plot shows higher RNU6-1099P RNA expression in tumor versus normal tissue (log2 FC = +1.114, t-test p < 0.001).
This table shows molecular features associated with RNU6-1099P in patient tissues and cancer cell lines. In patient samples, RNU6-1099P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
